Osage Partners related stories
All articles and analysis
VC-backed Selecta Biosciences debuts IPOWatertown, Massachusetts-based Selecta Biosciences, a clinical stage biotech company, has raised $70 million for its IPO after pricing its 5 million shares at $14 per share. The stock began trading June 22, 2016 on the NASDAQ under the ticker symbol "SELB." UBS Investment Bank and Stifel are the lead underwriters. Selecta Biosciences' backers included OrbiMed, Sanofi-Genzyme BioVentures, Ridgeback Capital Management, Osage University Partners, AJU IB Investment and Sphera Global Health Care Fund.
- Blade Therapeutics nabs $45 mln Series B
South San Francisco-based Blade Therapeutics, a biopharmaceutical company that treats fibrotic disease, has raised $45 million in Series B funding. Deerfield Management led the round with participation from other investors that included Pfizer Venture Investments, MPM Capital, Osage University Partners and Bristol-Myers Squibb. In conjunction with the funding, Dr. William Slattery and Cameron Wheeler of Deerfield Management and Dr. Elaine Jones of Pfizer Venture Investments have been added to Blade's board of directors.
- Blade Therapeutics nabs $45 mln Series B
South San Francisco-based Blade Therapeutics, a biopharmaceutical company that treats fibrotic disease, has raised $45 million in Series B funding. Deerfield Management led the round with participation from other investors that included Pfizer Venture Investments, MPM Capital, Osage University Partners and Bristol-Myers Squibb. In conjunction with the funding, Dr. William Slattery and Cameron Wheeler of Deerfield Management and Dr. Elaine Jones of Pfizer Venture Investments have been added to Blade's board of directors.
- New Leaf Venture Partners lead $65 Mln Series A for Aptinyx
Aptinyx Inc has completed a $65 million Series A financing round led by New Leaf Venture Partners. New investors Frazier Healthcare Partners, Longitude Capital and Osage University participated in the round. Existing investors including Adams Street Partners, LVP Life Science Ventures, PathoCapital, Goudy Park Capital, Beecken Petty O'Keefe & Company and Northwestern University also took part. Evanston, Illinois-based Aptinyx is abiopharmaceutical company developing treatments of neurological disorders.
- Carmack named CEO of PsiKick
PsiKick said May 9 that it named Philip J. Carmack as its CEO. Brendan Richardson, PsiKick’s founding CEO, has transitioned to VP of Business Development. Carmack was the CEO of Aptina Imaging Corp until it was sold to ON Semiconductor in June 2014. PsiKick is backed by investors including New Enterprise Associates.
- Capella Bioscience raises $15.5 mln in Series A funding
London-based Capella Bioscience Ltd raised 11 million pounds ($15.5 million) in a Series A funding round led by Advent Life Sciences, Medicxi Ventures and Osage University Partners. The new capital will support the advancement of Capella's therapeutic antibody discovery programs towards clinical evaluation. In connection with the financing, Bill Harrington of Osage University Partners will join the board in an observer role.
- Capella Bioscience raises $15.5 mln
Capella Bioscience Ltd said Tuesday it closed an 11 million pound ($15.5 million) Series A financing round. Investors include Advent Life Sciences, Medicxi Ventures, and Osage University Partners. London-based Capella is developing monoclonal antibody medicines.
- Iconic Therapeutics fetches $40 mln Series C
Iconic Therapeutics, a biopharmaceutical company focused on serious eye disorders, has raised $40 million in Series C funding. The investors included HBM Healthcare Investments, Cormorant Asset Management, Osage University Partners, MPM Capital, H.I.G. Capital and Lundbeckfund Ventures.
- Kymeta grabs $62 mln Series D
Redmond, Washington-based Kymeta Corp, a smart antenna developer, has secured $62 million in Series D funding. The investors included return backers Bill Gates, Lux Capital, Kresge Foundation and Osage University Partners.
- Millendo Therapeutics snags $62 mln Series B
Ann Arbor, Michigan-based Millendo Therapeutics (formerly known as Atterocor Inc), a biopharmaceutical company focused on treating orphan and specialty endocrine diseases, has raised $62 million in Series B funding. New Enterprise Associates Inc led the round. Other investors included Roche Venture Fund, Adams Street Partners, Altitude Life Science Ventures, Longwood Fund, Renaissance Venture Capital Fund, Frazier Healthcare Partners, Osage University Partners and 5AM Ventures.